Pictet Asset Management Sa Viridian Therapeutics, Inc.\De Transaction History
Pictet Asset Management Sa
- $83.4 Billion
- Q2 2023
A detailed history of Pictet Asset Management Sa transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Pictet Asset Management Sa holds 1,061,517 shares of VRDN stock, worth $22.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,061,517
Previous 1,042,965
1.78%
Holding current value
$22.9 Million
Previous $26.5 Million
4.82%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
82.7MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$116 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$105 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$103 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$97.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$95.6 Million7.39% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $861M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...